Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib-based consolidation in multiple myeloma post-SCT
NCT01706666Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Dec 2012
- Primary completion
- Jul 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in multiple myeloma (MM), sponsored by Mayo Clinic. Started Dec 2012; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01706666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01706666.